SLAMF7 and Miyoshi myopathy: Targeting non-overlapping (MU1067-hcAb, JK36-hcAb) or overlapping CD38 epitopes (WF211-hcAb) with our nanobody-based hcAbs during this period may not be helpful and underlines the need for antibodies targeting alternative target-proteins such as BCMA and SLAMF7 on the surface of MM cells 12, 48.